Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06014866 · ClinicalTrials.gov registry record
Conduction System Pacing With INGEVITY+
A clinical trial, sponsored by Duke University.
- Completed
- Registry status
- 1,383
- Enrollment target
NCT06014866: Completed study, sponsored by Duke University.
NCT06014866 is a clinical trial that has completed, run by Duke University. The registered enrollment target is 1,383 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06014866 has completed, sponsored by Duke University.
- COMPLETED
- Registry status
- 1,383 participants
- Enrollment target
Study Summary
The study is intended to evaluate the safety and effectiveness of the Boston Scientific INGEVITY+ cardiac pacing lead when implanted in the left bundle branch area (LBBA).
Primary Outcome
Adverse events that require correction with an invasive intervention or resulted in significant loss of device functionality.
Interventions
- DEVICE Cardiac pacing
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,383 participants |
| Start Date | 2023-11-13 |
| Est. Completion | 2024-08-27 |
What the finished NCT06014866 record still lists
NCT06014866 is an observational study that tracks outcomes without assigning an intervention. Its 1,383 participants enrollment target places it among the larger protocols in the corpus.
The record links to 0 conditions, and to 1 intervention - of which Cardiac pacing is the first listed.
NCT06014866 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT06014866 about?
NCT06014866 is a clinical study titled "Conduction System Pacing With INGEVITY+". The study is intended to evaluate the safety and effectiveness of the Boston Scientific INGEVITY+ cardiac pacing lead when implanted in the left bundle branch area (LBBA).
What is the current status of trial NCT06014866?
This trial is currently completed. The enrollment target is 1,383 participants. The study started on 2023-11-13. Estimated completion is 2024-08-27.
What interventions are being tested in trial NCT06014866?
The interventions under investigation include: Cardiac pacing (DEVICE).
Who is sponsoring clinical trial NCT06014866?
This trial is sponsored by Duke University, which has 1,725 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT06651281 · 1,380 participants · Phase 3
Extension Study of Long-term Safety and Efficacy of Tulisokibart in Participants With Crohn's Disease or Ulcerative Colitis (MK-7240-011)
- NCT05006131 · 1,395 participants
Pancreatic Cancer Screening for At-risk Individuals
- NCT07256392 · 1,370 participants · Phase 3
Long-term Efficacy and Safety Extension (LTE) Study of Barzolvolimab in Participants With Chronic Spontaneous Urticaria
- NCT02205762 · 1,400 participants · Phase 2
LCH-IV, International Collaborative Treatment Protocol for Children and Adolescents With Langerhans Cell Histiocytosis
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI